

PCT

WORLD INTELLECTUAL  
Property  
Office



INTERNATIONAL APPLICATION PUBLISHED UNDER

(51) International Patent Classification 6 : <b>C12Q 1/37, G01N 33/573, 33/543, 33/558</b>	A1	(11) International Publication Number: <b>WO 96/02667</b>
		(43) International Publication Date: <b>1 February 1996 (01.02.96)</b>

(21) International Application Number: <b>PCT/US95/08898</b>	(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).
(22) International Filing Date: <b>13 July 1995 (13.07.95)</b>	
(30) Priority Data: <b>08/275,887 14 July 1994 (14.07.94) US</b>	
(71) Applicant: AMGEN INC. [US/US]; Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, CA 91320-1789 (US).	
(72) Inventor: TAKACS, Laszlo; 816 Pamela Wood Street, Newbury Park, CA 91320 (US).	
(74) Agents: ODRÉ, Steven, M. et al.; Amgen Inc., Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, CA 91320-1789 (US).	

(54) Title: ASSAYS AND DEVICES FOR THE DETECTION OF EXTRAHEPATIC BILIARY ATRESIA

(57) Abstract

The present invention involves a variety of assay methods and devices for screening or diagnosing the occurrence of extrahepatic biliary atresia. In particular, the methods and devices involve the detection of dipeptidyl peptidase IV in a test sample as indicative of extrahepatic biliary atresia.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

**ASSAYS AND DEVICES FOR THE DETECTION OF  
EXTRAHEPATIC BILIARY ATRESIA**

5 1. Field of the Invention

The present invention relates to the diagnosis of extrahepatic biliary atresia. In particular, the invention involves the detection of dipeptidyl peptidase IV as an indication of the occurrence of 10 extrahepatic biliary atresia.

2. Background

Biliary atresia reflects total or partial agenesis of the biliary tree and usually affects 15 extrahepatic, rather than intrahepatic, bile ducts. Extrahepatic biliary atresia (EHBA) is a heterogeneous, rare disease, which is fatal if untreated. The incidence of EHBA varies considerably in various geographic areas but is estimated to 20 affect one in 18,000 live births each year in the United States alone. EHBA results from the discontinuous or failed development of bile ducts to the gut. Without the ducts, bile detergents begin to degrade the bile brush border of the bile capillary 25 epithelium and these materials leak to the venous sinusoids of the liver, ultimately connecting to the systemic circulation. In most cases, biliary atresia develops several weeks after birth, probably following inflammation and scarring of the bile 30 ducts. It is rarely found in still-borns or in the immediate neonatal period. The etiology of the inflammatory response is often unknown.

Affected children may appear normal at birth and are recognized due to progressive obstructive 35 jaundice at three to six weeks of age. This course reflects the pathologic changes within the bile ducts

- 2 -

in biliary atresia, namely, a dynamic evolution from a patent biliary tract at birth to progressive ductal obstruction and biliary cirrhosis.

Appropriate evaluations can usually exclude

5 other specific causes of neonatal obstructive jaundice, such as specific infections, galactosemia and cystic fibrosis, but differentiation between neonatal hepatitis and EHBA may be difficult due to the histologic similarities between their resultant pathologic changes. Early diagnosis is essential, because successful biliary decompression becomes increasingly unlikely with increasing patient age. Without surgical evaluation and reconstruction, prolonged biliary hypertension causes permanent and

10 progressive liver damage that may lead to metabolic complications, infection, sclerotizing cholangitis and cirrhosis, and may end in terminal liver insufficiency. Therefore, in the absence of findings positively securing an alternative diagnosis, biliary

15 atresia must be excluded.

20

Direct and total bilirubin values, liver enzymes, alkaline phosphatase and serum levels of bile acids usually rule out infections and metabolic disorders but will not clearly distinguish EHBA from neonatal hepatitis. Imaging studies involving radiographic evaluation or ultrasound examination of the gall bladder and of extrahepatic bile ducts may be helpful but are nonspecific. The placement of a nasoduodenal tube and collection of a 24 hour sample of duodenal fluid by gravity drainage may reveal the presence of bile (bilirubin can not be measured); bile excretion is strong evidence against a diagnosis of complete biliary atresia. Such a procedure, however, is invasive. Another invasive procedure is

25 percutaneous liver biopsy which requires

30

35 interpretation by an experienced physician.

If the diagnosis is still uncertain in excluding EHBA, a laparotomy must be performed before two months of age, because infants with EHBA will develop irreversible biliary cirrhosis if the operation is 5 deferred. Atretic bile ducts can be successfully reanastomosed in 5 to 10% of infants. EHBA is a progressive disease, and if corrective surgery is not performed prior to about eight weeks of age, there is only about a 25% chance of survival. If the 10 corrective procedure is not performed or fails, a liver transplant becomes necessary. It is therefore critical to detect EHBA between 2-8 weeks of age.

Upon diagnosis, EHBA is surgically treated. A few patients ( $\pm 15\%$ ) with EHBA have anatomic lesions 15 which are amenable to an anastomotic procedure providing direct suture of the gut mucosa to that of a proximally patent extrahepatic biliary tree. Most patients ( $\pm 85\%$ ) are not candidates for direct anastomosis. These patients had a hopeless prognosis 20 and short life span prior to the surgical approach by Kasai of hepatopancreaticoenterostomy which involves the direct surgical mucosa-to-mucosa anastomosis of the porta hepatis to the bowel. (Karrer et al., *Surg. Clin. North Am.* 70:1403-18 (1990) and Tagge et al., 25 *Ann. Surg.* 214:590-8 (1991)). In cases where permanent liver damage is present, the treatment of choice is liver transplantation (Ryckman et al., *Semin. Liver Dis.* 1:134-54 (1987); Wall W.J., *Can. Med. Assoc. J.* 139:21-8 (1988); and Esquivel et al., 30 *J. Pediatr.* 111:1039-45 (1987)).

With early diagnostic screening procedures, the number of unnecessary, early transplantations might be reduced by timely surgical intervention. In countries and areas where liver transplantation is 35 not available, early diagnosis followed by surgical

- 4 -

correction is the only chance of survival for patients with EHBA.

About 1/3 of all newborns appear jaundiced at birth. About 1/10 of these remain jaundiced after 5 approximately 10 days. These newborns would be candidates for an EHBA diagnostic. A screening program was recently advised for EHBA in the United Kingdom. The usefulness of the screening program, however, has been sharply debated due to the lack of 10 a simple and specific detection technology (Logan et al., *Lancet* 342:256 (1993)). Therefore, a simple and accurate non invasive test to evaluate EHBA would be invaluable to early diagnosis and treatment.

15

#### SUMMARY OF THE INVENTION

The present invention concerns a variety of assay methods for evaluating the probability of 20 extrahepatic biliary atresia. An exemplary method involves contacting a test sample with a protease substrate reactive with dipeptidyl peptidase IV, thereby initiating a reaction; and detecting the reaction of the substrate or the formation of a 25 detectable reaction product. The reaction or presence of the reaction product results from the presence of dipeptidyl peptidase IV in the test sample and is indicative of extrahepatic biliary atresia. The substrate may be a chromogenic 30 substrate, and the presence of dipeptidyl peptidase IV is indicated by the production of a colored reaction product. Possible substrates include Xaa-Pro-para-nitro-analide and Xaa-Pro-coumarin, wherein 35 Xaa is any naturally occurring or synthetic amino acid.

Another possible assay for detecting the presence of dipeptidyl peptidase IV in a test sample involves contacting the test sample with a first antibody specific for dipeptidyl peptidase IV,

5 thereby producing antibody-bound dipeptidyl peptidase IV. The antibody-bound dipeptidyl peptidase IV is then contacted with a detection reagent, such as a protease substrate, a labeled second antibody specific for dipeptidyl peptidase IV, or a second

10 antibody specific for dipeptidyl peptidase IV which indirectly binds a detectable label, thereby forming a detectable reaction product. The formation of a detectable reaction product results from the presence of dipeptidyl peptidase IV in the test sample and

15 indicates the probability of extrahepatic biliary atresia.

The assays may be developed in the form of assay devices for analyzing a test sample and evaluating the probability of extrahepatic biliary atresia. In

20 a basic form, such devices include a solid phase containing or coated with a substrate reactive with dipeptidyl peptidase IV, wherein the substrate reacts with dipeptidyl peptidase IV present in the test sample and produces a detectable reaction indicative

25 of extrahepatic biliary atresia.

Another analytical device for determining the presence or amount of dipeptidyl peptidase IV in a test sample involves a strip of porous material having a proximal end and a distal end, wherein the

30 test sample can travel from the proximal end to the distal end by capillary action. An antibody is immobilized in a capture site positioned between the proximal and distal ends, wherein the antibody binds dipeptidyl peptidase IV. An indicator reagent,

35 positioned at the capture site or positioned on said strip upstream from said capture site, may be a

- 6 -

labeled antibody which binds to dipeptidyl peptidase IV and produces a detectable signal at the capture site thereby indicating the presence or amount of dipeptidyl peptidase IV in the test sample. The 5 device may optionally include an application pad in fluid flow contact with the proximal end of the strip, wherein the application pad receives the test sample and contains the indicator reagent. In addition, the capture reagent may be immobilized 10 within the strip in the form of one or more discrete capture sites.

#### BRIEF DESCRIPTION OF THE DRAWINGS

15

Figure 1 depicts dipeptidyl peptidase IV and leucine aminopeptidase activities in urine samples of control and EHBA patients.

20

Figure 2 depicts dipeptidyl peptidase IV activity in serum samples.

Figure 3 depicts leucine aminopeptidase activity in serum samples.

25

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention involves the diagnosis of extrahepatic biliary atresia (EHBA) via the detection of elevated urinary and serum dipeptidyl peptidase IV 30 activity levels. Dipeptidyl peptidase IV (DPPIV; E.C.N. 3.4.14.5 also known as thymocyte costimulating protein or CD26) is a protease with a very specific tissue distribution. It is located on the luminal side of the epithelial cells lining the bile ducts 35 (see Bristol et al., *J. Immunol.* **148**:332-338 (1992) and **149**:367-372 (1992)). The hypothesis leading to

the present invention was that if unreleased bile detergents degraded the epithelium, then DPPIV which was under pressure in the incomplete ducts may leak through the tight junctions between the cells and 5 pass into the blood. This suggested examining the patient's blood and urine for DPPIV-like activity.

DPPIV and leucine aminopeptidase (LAP, CD 13, E.C.N. 3.4.11.2) measurements were performed on serum and urine samples of patients previously diagnosed 10 with EHBA and of patients with jaundice due to ABO incompatibility or viral hepatitis. The results indicated the differential diagnostic potential of the assay and demonstrated that elevated DPPIV activity is indicative of EHBA. A DPPIV urine level 15 of typically at least 1 nmol/min/ml, or more preferably of at least 2 nmol/min/ml, or a serum level of at least 15 nmol/min/ml was found to be indicative of EHBA.

The present invention, therefore, provides 20 inexpensive and easy to perform assays for use in screening for EHBA. In addition, changes in serum levels of both LAP and DPPIV activities may be of additional help to already existing enzyme and other diagnostic tests for the differential diagnosis of 25 EHBA. Moreover, the assays and devices of the present invention may be used to monitor patients following corrective surgery.

One embodiment of the present invention involves 30 a chemical assay for DPPIV. The assay uses an enzyme substrate which reacts with DPPIV to form a detectable reaction product. Alternatively, the rate of the reaction of the substrate can be monitored to determine the presence or amount of DPPIV in a test 35 sample. Suitable enzyme substrates include, but are not limited to, dipeptide substrates such as Xaa-Pro-

para-nitro-analide (Xaa-Pro-PNA) or Xaa-Pro-coumarin. The variable amino acid, Xaa, can be any naturally occurring or synthetic amino acid. An exemplary dipeptide substrate is Gly-Pro-para-nitro-analide 5 (Gly-Pro-PNA). At a wavelength of 405 nanometers, the substrate has no absorbance; however, if the dipeptide substrate is cleaved (after the Pro) due to the presence of DPPIV, the formation of a reaction product can be visualized spectrophotometrically, as 10 a yellow-green color is produced. Other substrates, such as Xaa-Pro-coumarin, can be visualized spectrofluorometrically as a fluorescent emission is produced by the reaction.

Assays embodying such reagents and reactions can 15 be performed in any suitable reaction vessel, for example, a test tube or well of a microtiter plate. Alternatively, assay devices may be developed in disposable form such as dipstick or teststrip device formats which are well known to those skilled-in-the- 20 art and which provide ease of manufacture and use. Such disposable assay devices may be packaged in the form of kits containing all necessary materials, reagents and instructions for use. The kits could be provided to parents of those newborns whose jaundice 25 did not disappear after approximately 10 days. These newborns could be closely monitored by the assays of the present invention to detect the presence or amount of DPPIV in a test sample (preferably urine for home assay detection) and thereby evaluate the 30 probability of extrahepatic biliary atresia.

Assay devices of the present invention could advantageously be formatted as dipstick or teststrip devices. For example, a dipstick may be made from a piece of bibulous material containing a chromogenic 35 substrate for DPPIV. Alternatively, the dipstick could be made from a nonporous material on which the

- 9 -

substrate is coated. Upon contacting the device with the desired test sample, the substrate and any DPPIV present in the sample would interact to form a detectable reaction upon the device.

5        In an alternative embodiment, the device may be a teststrip, wherein the substrate is contained in one or more zones along the length of a strip of bibulous material. Upon contact of one end of the strip with the desired test sample, the liquid sample  
10      migrates along the bibulous material. The reaction of the substrate and production of a detectable signal indicates the presence of DPPIV in the test sample. In a multi-zoned device, the number of discrete or isolated zones along the length of the  
15      strip which produce a detectable signal may also indicate the quantity of DPPIV present in the test sample. Alternatively, a major portion of the teststrip may contain the substrate. The length of the colored reaction formed in a teststrip having  
20      such a single, elongated substrate zone may be used to indicate the presence or amount of DPPIV in the test sample.

In an alternative assay embodiment, the rate at which the reaction occurs may be detected as an  
25      indication of the quantity of DPPIV present in the test sample. For example, the rate at which the substrate is reacted may be used to indicate the quantity of DPPIV present in the test sample.  
Alternatively, the rate at which the reaction product  
30      is formed may be used to indicate the quantity of DPPIV present in the test sample.

In yet another embodiment, a capture or binding assay may be performed to detect and/or quantitate the protease. For example, an antibody reactive with  
35      DPPIV protein, but which does not interfere with peptidase activity, may be immobilized upon a solid

- 10 -

phase. The test sample is passed over the immobile antibody, and DPPIV, if present, binds to the antibody and is itself immobilized for detection. A substrate may then be added, and the reaction product 5 may be detected to indicate the presence or amount of DPPIV in the test sample. For the purposes of the present description, the term "solid phase" may be used to include any material or vessel in which or on which the assay may be performed and includes, but is 10 not limited to, porous materials, nonporous materials, test tubes, wells, slides, etc.

In an exemplary teststrip device, a test sample application pad is optionally attached to one end of a porous strip. The strip contains an immobilized 15 antibody which will bind to and thereby immobilize DPPIV at a predetermined site for subsequent detection. Optionally, the device may include an end of assay indicator which is positioned at the distal end of the teststrip away from the test sample 20 contact site. The end of assay indicator produces a detectable signal upon contact with the test sample or an assay reagent thereby indicating that the assay is complete.

A test sample application pad may be a portion 25 of the porous strip itself or a material in fluid-flow contact with the end of the porous strip, referred to as the proximal end, such that the test sample can pass or migrate from the application pad to the porous strip. Fluid-flow contact can include 30 physical contact of the application pad to the porous strip as well as the separation of the application pad from the porous strip by an intervening space or additional material which still allows fluid to flow between the application pad and the porous strip. 35 Substantially all of the application pad can overlap the porous strip to enable the test sample to pass

through substantially any part of the application pad to the proximal end of the porous strip.

Alternatively, only a portion of the application pad might be in fluid-flow contact with the porous strip.

5 The application pad can be any material which can transfer the test sample to the porous strip.

The porous strip of the assay device can be any suitably absorbent, porous, bibulous, chromatographic or capillary possessing material through which a test 10 sample containing the analyte can be transported by a capillary or wicking action. Natural, synthetic, or naturally occurring materials that are synthetically modified, can be used as the porous strip including, but not limited to: cellulose materials such as 15 paper, cellulose, and cellulose derivatives such as cellulose acetate and nitrocellulose; fiberglass; cloth, both naturally occurring (e.g., cotton) and synthetic (e.g., nylon); porous gels such as silica gel, agarose, dextran, and gelatin; porous fibrous 20 matrixes; starch based materials, such as cross-linked dextran chains; ceramic materials; films of polyvinyl chloride and combinations of polyvinyl chloride-silica; and the like. The porous strip should not interfere with the production of a 25 detectable signal. The porous strip should have a reasonable inherent strength, or strength can be provided by means of a supplemental support.

The particular dimensions of the porous strip will be a matter of convenience, depending upon the 30 size of the test sample involved, the assay protocol, the means for detecting and measuring the signal, and the like. For example, the dimensions may be chosen to regulate the rate of fluid migration as well as the amount of test sample to be imbibed by the porous 35 strip.

- 12 -

In one possible teststrip device of the present invention, a DPPIV substrate and/or DPPIV capture antibody may be immobilized on the porous strip to form at least one analyte detection site, i.e., that 5 region of the porous strip having one or more assay reagents non-diffusively attached thereto. In another device embodiment, the measurement or detection region of the teststrip may include a plurality of sites containing a DPPIV substrate and/or immobilized anti-DPPIV antibody. Optionally, 10 the different detection sites may contain different amounts of substrate and/or immobilized anti-DPPIV antibody, i.e., a higher amount in the first detection site and lesser amounts in subsequent 15 sites. For example, if 20 nanograms of antibody captures the equivalent of 1 nmol/min/ml of DPPIV, then the first detection site of a urinary assay device might contain 50 nanograms of anti-DPPIV antibody while the subsequent sites contain 10, 20, 20 30, etc. nanograms of antibody. Upon the addition of test sample, the number of sites displaying a detectable signal provides a quantitative indication 25 of the amount of DPPIV present in the sample. The detection sites may be configured in any suitably detectable shape and are typically in the shape of a bar spanning the width of the teststrip.

Optionally, the multi-capture site device may be prepared such that if a threshold amount of DPPIV is not present in the test sample, then substantially 30 all of the DPPIV will bind to the antibody in the first capture site and thus become immobilized at that site. If a greater than threshold amount of DPPIV is present in the test sample, the remaining 35 DPPIV will bind to subsequent detection zones of immobilized antibody along the length of the teststrip. The greater the amount of DPPIV in the

- 13 -

test sample, the greater the number of capture sites that will display a detectable signal due to the presence of DPPIV. As will be appreciated by those skilled-in-the-art, devices containing multiple DPPIV 5 substrate sites can also be produced wherein the amount of substrate in the individual sites is designed to produce a quantitative or semiquantitative assay result.

In yet another assay embodiment, the presence or 10 quantity of DPPIV protein may be directly detected without measuring DPPIV activity. Qualitative or quantitative immunoassays and devices may be produced with any suitable anti-DPPIV antibody (e.g., anti-CD26 antibody (TA-1) Coulter Corporation, Miami, FL 15 or as produced as illustrated in Fleischer B., CD26: A surface protease involved in T-cell activation. *Immunology Today* 15:181-184 (1994)). Both polyclonal and monoclonal antibodies can be produced in accordance with methods that are well-known to and 20 reliably used by those skilled-in-the-art.

There are several well known immunoassay methods using immunoreactants, wherein at least one of the immunoreactants is labeled with a detectable component so as to be analytically identifiable. For 25 example, the "sandwich" or "two-site" technique may involve the formation of a ternary complex between an antigen analyte such as DPPIV and two antibodies. A convenient method of detecting complex formation in such a technique is to provide one labeled antibody 30 and an unlabeled antibody bound to a solid phase support such that the complex can readily be isolated. In this example, the amount of labeled antibody associated with the solid phase is directly proportional to the amount of analyte in the test 35 sample.

An alternative technique is the "competitive" assay. In one example of a competitive assay, the capture mechanism again may use an antibody attached to an insoluble solid phase, but a labeled reagent (rather than a labeled antibody) competes with the analyte present in the test sample for binding to the immobilized antibody. Similarly, an immobilized reagent can compete with the analyte of interest for a labeled antibody. In these competitive assays, the quantity of captured labeled reagent is inversely proportional to the amount of analyte present in the sample.

Examples of devices based upon these principles include those described in the following patents and patent applications. Deutsch et al. describe a chromatographic teststrip device in U.S. Pat. Nos. 4,094,647, 4,235,601 and 4,361,537. The device comprises a material capable of transporting a solution by capillary action. Different areas or zones in the strip contain the reagents needed to perform a binding assay and to produce a detectable signal as the analyte is transported to or through such zones. The device is suited for chemical assays as well as binding assays which are typified by the binding reaction between an antigen and a complementary antibody.

Many variations on the device of Deutsch et al. have been subsequently disclosed. For example, Tom et al. (U.S. Pat. No. 4,366,241) disclose a bibulous support with an immunosorbing zone, containing an immobilized specific binding member. The test sample is applied to the immunosorbing zone, and the assay result is read at the immunosorbing zone.

Weng et al. (United States Patent Nos. 4,740,468 and 4,879,215) also describe a teststrip device and

methods for performing a binding assay. The device is used with a test solution containing the test sample, suspected of containing the analyte of interest, and a labeled specific binding member which 5 binds to the analyte. Greenquist et al. (United States Patent Nos. 4,806,311 and 4,806,312) describe a layered assay device for performing binding assays similar to those of Weng et al.

The term "label", as used herein, refers to any 10 substance which directly or indirectly attaches to another binding member assay reagent or analyte and which is capable of producing a signal that is detectable by visual or instrumental means. Various suitable labels for use in the present invention can 15 include chromogens; catalysts; fluorescent compounds; chemiluminescent compounds; radioactive labels; direct visual labels including colloidal metallic and non-metallic particles, dye particles, enzymes or substrates, or organic polymer latex particles; 20 liposomes or other vesicles containing signal producing substances; and the like. The label may indirectly attach to an antibody specific for DPPIV by means of additional ligands such as avidin/biotin. For example, a biotinylated antibody may bind an 25 avidin/label reagent which binds to the biotinylated antibody before or after the antibody binds to DPPIV.

Rosenstein (European Patent Office Publication No. 0 284 232) and Campbell et al. (United States Patent Nos. 4,703,017) describe assay methods and 30 devices for performing specific binding assays, wherein the preferred detectable label is a colored particle consisting of a liposome containing a dye. Bahar, et al. (United States Patent No. 4,868,108) describe an assay method and device for performing a 35 specific binding assay, wherein the device involves a multizoned support. Eisinger et al. (United States

- 16 -

Patent No. 4,943,522) describe an assay method and a device for performing specific binding assays, using a multizoned large-pored lateral flow membrane through which test sample is transported by capillary 5 action.

Hochstrasser (U.S. Pat. 4,059,407) discloses a dipstick device which can be immersed in a biological fluid for a semi-quantitative measurement of the analyte in the fluid. The semi-quantitative 10 measurement of the analyte is accomplished by using a series of reagent-containing pads, wherein each pad in the series will produce a detectable color (i.e., a positive result) in the presence of an increasing amount of analyte. Also of interest in the area of 15 dipstick devices are U.S. Pat. Nos. 3,802,842, 3,915,639 and 4,689,309.

Grubb et al. (U.S. Pat. No. 4,168,146) describe the use of a porous teststrip material to which an antigen-specific antibody is immobilized by covalent 20 binding to the strip. The teststrip is immersed in a solution suspected of containing an antigen, and capillary migration of the solution up the teststrip is allowed to occur. Variations on such a teststrip are disclosed in U.S. Pat. No. 4,435,504 which 25 employs a two enzyme indicator system; U.S. Pat. No. 4,594,327 which discloses the addition of a binding agent to whole blood samples which causes the red blood cells to aggregate at the area of the strip adjacent to the air/liquid interface; and U.S. Pat. 30 No. 4,757,004 which discloses a means for controlling the shape of the fluid front migrating along the teststrip. The assay principle is further described in Zuk et al., Enzyme Immunoassay - A Quantitative Immunoassay Requiring No 35 Instrumentation, *Clinical Chemistry*, 31(7): 1144-1150 (1985).

- 17 -

Further examples of strip-type diagnostic devices include the following. Swanson et al. (EP 088 636) describe an apparatus for the quantitative determination of an analyte involving a fluid-permeable solid medium containing a predetermined number of successive spaced reaction zones. Freisen et al. (U.S. Patent Number 4,861,711) describe a sheet-like diagnostic device containing several functional sectors through which the sample must pass. At least one of the sectors includes an immobilized reagent having a biological affinity for the analyte or an analyte complex.

Also of interest in the area are Tanswell et al. (United States Patent No. 4,642,930), Valkirs et al. (United States Patent No. 4,727,019), Wolters et al. (U.S. Patent Number 4,343,896), and Parikh et al. (U.S. Patent Number 4,298,685), Gordon et al. (U.S. Patent Number 4,956,302), Gordon et al. (U.S. Patent Number 4,960,691) and Bolz et al. (United States Patent No. 4,020,151).

As will be appreciated from this description of possible device formats, there is significant activity in the field of disposable assay devices. There is a growing demand for devices that require few or no manipulative steps to perform the desired assay, for devices that can be used by relatively untrained personnel, and for devices that provide results which are minimally affected by variations in the manner in which the assay is performed. Further considerations are the ease with which the resultant detection signal may be observed as well as the ease with which any signal substance immobilized at the detection site can be distinguished from the signal substance which passed through the detection site.

- 18 -

The following assay results describe dipeptidyl peptidase IV and CD13 leucine/neutral amino-peptidase (LAP, E.C.N. 3.4.11.2) measurements in diagnosing EHBA. DPPIV and CD13 LAP are large membrane-associated proteins (approximately 100 kD) expressed in the liver on bile canaliculi and biliary epithelium, on the surface of gut epithelium and on some kidney canaliculi, as well as on cells of hematopoietic origin.

10 The results demonstrate the utility of the DPPIV test as a procedure for the detection of EHBA. The use of urinary DPPIV measurements, as well as the routine physical examination of the patient and study of stool and urine for signs of jaundice, provides a 15 useful screening procedure for EHBA. Patients with high urinary DPPIV activity may be further tested for serum enzymes. The number of EHBA-suspect patients at this point should be low enough not to overload radiological, ultrasonographic and histological 20 (biopsy) diagnostic capacity of pediatric hospitals, thereby ensuring early diagnosis and treatment of EHBA.

25

## EXAMPLES

### Example 1 Detection of DPPIV

30 DPPIV and LAP activities were measured in urine and serum samples of known EHBA patients. Assays were performed six times prior to surgery. The patients (average age: 8 weeks) had been admitted to the hospital because of persistent jaundice. All of 35 the cases had been histologically diagnosed by needle biopsies.

- 19 -

Enzyme activities were measured in triplicates at 24°C, by mixing 100 µl or 50 µl of sample to 100 µl or 150 µl of a reaction buffer (DPPIV or LAP, respectively) containing 200 µM of chromogenic substrate in 0.1M Tris buffered Triton X-100 (0.1% v/v) at pH:7. The substrates were Gly-Pro-PNA (for DPPIV and Leu-PNA for LAP (both materials are commercially available from Bachem, San Diego, CA).

The mixtures were incubated for 30 minutes in 96-well microplates. Optical density readings were taken four times during incubation with a 405 nm filter in an ELISA reader, according to the manufacturer's instructions. Enzyme activity was expressed in nmol/min/ml based on the progression curve calculated from the concentration of hydrolyzed substrates. Purified DPPIV may be used as a positive control against which to compare the DPPIV assay results. Purified DPPIV may be made in accordance with the method described in Bristol et al., *J. Immunol.* 149:367-372 (1992). Reaction buffer, without substrate, served as the negative control. The negative control did not show an increase in the concentration of hydrolyzed substrate, suggesting that the substrates were stable in the assay.

Fifty healthy volunteers provided urine samples for the initial control studies. All volunteers had been tested for creatinine in the urine and showed normal values. Urinary enzyme activities were not corrected, because of the very low level of enzyme activity present in normal urine. In addition to the healthy volunteers, urine and blood samples were collected from five age-matched healthy neonates (with parental consent). For comparison with EHBA patients, LAP and DPPIV measurements were performed on serum and urine samples from four neonates with jaundice due to ABO incompatibility and from sixteen

- 20 -

children (average age: 9.5 years) with viral hepatitis. Routine laboratory tests included GTP, GOT,  $\gamma$ GT, AP and bilirubin measurements. Statistical analysis was performed with Sigma Plot 5.0 (Jandel 5 Scientific Corporation, San Rafael, CA).

The urinary DPPIV and LAP activity of the 50 normal young volunteers (average age: 27 years) were  $0.199 \pm 0.224$  nmol/min/ml and  $0.078 \pm 0.272$  nmol/min/ml, respectively. The four urine samples 10 from age-matched controls showed low or barely detectable activity ( $0.06 \pm 0.05$  nmol/min/ml for DPPIV and  $0.820 \pm 0.215$  nmol/min/ml for LAP). EHBA patients had  $6.927 \pm 3.45$  nmol/min/ml and  $8.52 \pm 13.05$  nmol/min/ml urinary activities for DPPIV 15 and LAP, respectively, with DPPIV differing significantly ( $p<0.05$ ) from control. Figure 1 depicts the urinary DPPIV activity of age-matched control and EHBA patients. Measurements in the EHBA group were performed six times. The number of 20 patients in each group is indicated (urine samples of two patients were measured two times). The horizontal bars indicate the standard error. A single high value (over 15 nmol/min/ml) of LAP activity is offscale on the figure.

25 When serum DPPIV activity was compared between the controls and different disease groups (Figure 2), it became clear that EHBA patients had significantly higher DPPIV activity ( $p<0.05$ ) than normal, as well as higher DPPIV activity than patients with jaundice 30 due to ABO incompatibility. Viral hepatitis patients presented two groups; one with values as low as the control (7 of 16 patients) and another with DPPIV activity (24-60 nmol/min/ml) values as high as the EHBA patients. Compared to controls, LAP activity 35 was significantly elevated ( $p<0.05$ ) in hepatitis patients and slightly elevated in three of four EHBA

- 21 -

patients. Figure 3 illustrates the serum LAP activity measurements. A comparison of normal control and different disease groups is indicated. Measurements in the EHBA group were done seven times.

5 The number of patients in each group is indicated, and the horizontal bars indicate the standard error.

These results illustrate that urinary measurement of DPPIV activity provides a method of

10 screening for EHBA. DPPIV levels of at least 1-3 nmol/min/ml indicate EHBA. Elevated DPPIV levels in serum, when compared to LAP and other enzymes, have a potential differential diagnostic value, e.g., GPT and LAP activities are higher in viral hepatitis

15 than in EHBA patients (data not shown).

CD26, DPPIV and CD13 LAP are large membrane-associated proteins (approximately 100 kD) expressed in the liver on bile canaliculi and biliary epithelium, on the surface of gut epithelium and on

20 some kidney canaliculi, as well as on cells of hematopoietic origin. The enzymes present in the serum are probably processed forms and most likely have considerably lower molecular masses. Elevated serum levels show good linear correlation with

25 elevated urinary levels for both enzymes ( $r_{LAP}=0.843$ ,  $r_{DPPIV}=0.87$ ) suggesting that the serum enzyme can be filtered or that it is secreted into the urine. Since both enzymes are expressed in kidney canaliculi, urinary infections may represent a

30 differential diagnostic problem when high levels of DPPIV or LAP are measured in the urine.

- 22 -

Example 2  
DPPIV Dipstick Assay

A chromogenic substrate, such as Gly-Pro-PNA, is  
5 applied to a strip of filter paper and dried. The  
amount of substrate may be predetermined such that  
the reaction with DPPIV will produce a visually  
detectable reaction, e.g., approximately 80 nmol/cm<sup>2</sup>  
of substrate/reaction site may be used. The tip of  
10 the paper is subsequently contacted with a urine  
sample. If the test sample contains DPPIV, the  
substrate reacts with the DPPIV and produces a  
detectable change in color.

15

Example 3  
DPPIV Teststrip Assay

A chromogenic substrate (Gly-Pro-PNA,  
20 80 nmol/cm<sup>2</sup>) is applied to and dried in one or more  
isolated zones in the form of bars across the width  
of an elongated strip of filter paper. The tip of  
the paper is subsequently contacted with an fluid  
test sample such as serum or urine. The sample wicks  
25 through the test strip, thereby contacting the  
isolated substrate. If the test sample contains  
DPPIV, the substrate reacts with the DPPIV and  
produces a detectable change in color in one or more  
of the detection zones. By varying the amount of  
30 substrate present in the individual zones, the  
production of a detectable signal may be  
quantitative.

Example 4  
DPPIV Teststrip Device

In the present invention, binding assays may 5 involve the specific binding of DPPIV and/or an indicator reagent (comprising a label directly or indirectly attached to an antibody specific for DPPIV) to a capture reagent (comprising a second anti-DPPIV antibody). The capture reagent 10 immobilizes DPPIV on a chromatographic material or at least slows the migration of the analyte or indicator reagent through the chromatographic material.

The label, as described above, allows the indicator reagent to produce a detectable signal that 15 is related to the presence or amount of analyte in the test sample. The selection of a particular label is not critical, but the label will be capable of generating a detectable signal either by itself, such as a visually detectable signal generated by colored 20 organic polymer latex particles, or in conjunction with one or more additional signal producing components, such as an enzyme/substrate signal producing system.

The capture reagent, in the DPPIV assay, is used 25 to facilitate the observation of the detectable signal by substantially separating DPPIV and/or the indicator reagent from other assay reagents and the remaining components of the test sample. Typically, the capture reagent is immobilized on the 30 chromatographic material to form a "capture site", i.e., a region of the chromatographic material having one or more capture reagents non-diffusively attached thereto.

The assay device may include a chromatographic 35 material having a proximal end and a distal end, wherein the test sample can travel from the proximal

- 24 -

end to the distal end by capillary action. The chromatographic material contains the capture reagent, i.e., anti-DPPIV antibody, which is immobilized in a capture site and which is capable of 5 binding to DPPIV. An optional test sample application pad may be provided in fluid flow contact with the proximal end of the chromatographic material. The application pad may be used to receive the test sample and pass the sample to the 10 chromatographic material. The application pad may optionally contain a diffusive indicator reagent capable of migrating from the application pad to the chromatographic material. The indicator reagent is preferably capable of binding to DPPIV, e.g., a 15 labeled second anti-DPPIV antibody. The binding of the indicator reagent to DPPIV results in the formation of a ternary or sandwich complex and a detectable signal at the capture site, thereby indicating the presence or amount of DPPIV in the 20 test sample.

The capture reagent can be positioned upon or within the chromatographic material in a variety of configurations. In alternative embodiments, the capture reagent can be distributed in any pattern 25 convenient for detection including, but not limited to, bars, stripes, numerals, letters, dots and symbols such as "+/-", "%" or the like which display the detectable signal upon completion of the assay.

The assay method is easily performed by placing 30 a test sample suspected of containing the analyte onto the application pad, thereby contacting the indicator reagent. The test sample and the indicator reagent are transferred to the chromatographic material, and migrate through the chromatographic 35 material to contact the capture reagent, resulting in

- 25 -

the production of a detectable signal at the capture site.

- 5        The foregoing descriptions of the specific embodiments so fully reveal the general nature and applicability of the present invention that others can readily modify, adapt and/or optimize such specific embodiments for an assortment of assay
- 10      methods and devices, using a variety of reagents and materials, without departing from the present inventive concept. Any such modifications and adaptations are intended to be embraced within the meaning and range of equivalents of this invention.
- 15      It is also to be understood that the phraseology and terminology employed herein are for the purpose of description and not of limitation. All articles, applications and patents contained in this description of the present invention are incorporated
- 20      by reference.

## CLAIMS

What is claimed is:

- 5 1. A method for evaluating the probability of extrahepatic biliary atresia, the method comprising the steps of:
  - a) contacting a test sample with a protease substrate reactive with dipeptidyl peptidase IV,
  - 10 b) detecting the reaction of said substrate or the formation of a detectable reaction product, wherein the reaction or presence of the reaction product results from the presence of dipeptidyl peptidase IV
  - 15 in the test sample and is indicative of extrahepatic biliary atresia.
- 20 2. The method according to Claim 1, wherein said substrate is a chromogenic substrate and the presence of dipeptidyl peptidase IV is indicated by the production of a colored reaction product.
- 25 3. The method according to Claim 1, wherein said substrate is selected from the group consisting of Xaa-Pro-para-nitro-analide and Xaa-Pro-coumarin, wherein Xaa is any naturally occurring or synthetic amino acid.
- 30 4. The method according to Claim 3, wherein said substrate is Gly-Pro-para-nitro-analide.
- 35 5. The method according to Claim 1, further comprising the step of first binding the dipeptidyl peptidase IV in the test sample to an anti-dipeptidyl peptidase IV antibody.

6. An assay for detecting the presence of dipeptidyl peptidase IV in a test sample, wherein the presence of dipeptidyl peptidase IV is indicative of extrahepatic biliary atresia, the assay comprising

5 the steps of:

- contacting the test sample with a first antibody specific for dipeptidyl peptidase IV, thereby producing antibody-bound dipeptidyl peptidase IV;
- 10 contacting the antibody-bound dipeptidyl peptidase IV with a detection reagent selected from the group consisting of a protease substrate, a labeled second antibody specific for dipeptidyl peptidase IV, and a second antibody specific for dipeptidyl peptidase IV which indirectly binds a
- 15 detectable label, thereby forming a detectable reaction product; and
- c) detecting the formation of said detectable reaction product resulting from the presence of dipeptidyl peptidase IV in the test sample.

20

7. The assay according to Claim 6, wherein said detection reagent is a protease substrate selected from the group consisting of Xaa-Pro-para-nitro-analide and Xaa-Pro-coumarin, wherein Xaa is any

25 naturally occurring or synthetic amino acid.

8. The assay according to Claim 6, wherein said detection reagent is a labeled anti-dipeptidyl peptidase IV antibody.

30

9. The assay according to Claim 6, wherein said first antibody is immobilized in an isolated site of a dipstick or teststrip.

35 10. An assay device for analyzing a test sample and evaluating the probability of extrahepatic biliary

atresia, comprising: a solid phase containing or coated with a substrate reactive with dipeptidyl peptidase IV, wherein said substrate reacts with dipeptidyl peptidase IV present in the test sample 5 and produces a detectable reaction indicative of extrahepatic biliary atresia.

11. The device according to Claim 10, wherein said substrate is a chromogenic substrate and the presence 10 of dipeptidyl peptidase IV is indicated by the production of a colored reaction product.

12. The device according to Claim 10, wherein said substrate is selected from the group consisting of 15 Xaa-Pro-para-nitro-analide and Xaa-Pro-coumarin, wherein Xaa is any naturally occurring or synthetic amino acid.

13. The device according to Claim 10, wherein said 20 solid phase is in the form of an elongated strip of porous material.

14. An analytical device for determining the presence or amount of dipeptidyl peptidase IV in a 25 test sample, comprising:

a strip of porous material having a proximal end and a distal end, wherein the test sample can travel from said proximal end to said distal end by capillary action;

30 an antibody immobilized in a capture site positioned between said proximal and distal ends, wherein said antibody binds dipeptidyl peptidase IV; and

35 an indicator reagent at said capture site or positioned on said strip upstream from said capture site, wherein said indicator reagent is a labeled

- 29 -

antibody which binds to dipeptidyl peptidase IV and produces a detectable signal at said capture site thereby indicating the presence or amount of dipeptidyl peptidase IV in the test sample.

5

15. The device according to Claim 14, further comprising an application pad in fluid flow contact with said proximal end of said strip, wherein said application pad receives the test sample and contains 10 said indicator reagent.

16. The device according to Claim 14, wherein said capture reagent is immobilized within said strip to form at least one discrete capture site.

15

17. The device according to Claim 14, wherein said capture reagent is immobilized within said strip in the form of two or more separate capture sites.

20 18. A method for evaluating the probability of extrahepatic biliary atresia, comprising: testing a urine sample for the presence of dipeptidyl peptidase IV in said test sample, wherein the presence of dipeptidyl peptidase IV in an amount of at least 1 25 nmol/min/ml is indicative of extrahepatic biliary atresia.

19. A method for evaluating the probability of extrahepatic biliary atresia, comprising: testing a 30 serum sample for the presence of dipeptidyl peptidase IV in said test sample, wherein the presence of dipeptidyl peptidase IV in an amount of at least 15 nmol/min/ml is indicative of extrahepatic biliary atresia.

35

- 30 -

20. An assay device for analyzing a test sample and evaluating the probability of extrahepatic biliary atresia, comprising: a substrate reactive with dipeptidyl peptidase IV, wherein said substrate 5 reacts with dipeptidyl peptidase IV present in the test sample and produces a detectable reaction indicative of extrahepatic biliary atresia.





Figure 1






Figure 3

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 95/08898

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C12Q1/37 G01N33/573 G01N33/543 G01N33/558

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>CHEMICAL ABSTRACTS, vol. 104, no. 11, 17 March 1986 Columbus, Ohio, US; abstract no. 86338, S. MAEYAMA. 'Clinical significance of glycylproline-dipeptidyl-aminopeptidase activities in sera of various hepatobiliary disease cases.' page 471; column 1; see abstract &amp; SEI MARIANNA IKA DAIGAKU ZASSHI , vol. 13, no. 2, 1985 pages 236-250, ---</p>	1-20
Y	<p>US,A,4 191 808 (T. NAGATSU ET AL.) 4 March 1980 see abstract; claims ---</p>	1-4, 6, 7, 10-13, 18-20
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*'A' document defining the general state of the art which is not considered to be of particular relevance
- \*'E' earlier document but published on or after the international filing date
- \*'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*'O' document referring to an oral disclosure, use, exhibition or other means
- \*'P' document published prior to the international filing date but later than the priority date claimed

\*'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*'Z' document member of the same patent family

Date of the actual completion of the international search

3 November 1995

Date of mailing of the international search report

11.01.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl  
Fax (+ 31-70) 340-3016

Authorized officer

Griffith, G

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 95/08898

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US,A,4 191 809 (T. NAGATSU ET AL.) 4 March 1980 see abstract; claims ---	1-3,6,7, 10-13, 18-20
Y	CHEMICAL ABSTRACTS, vol. 113, no. 5, 30 July 1990 Columbus, Ohio, US; abstract no. 36831, G. W. MCCUAUGHAN ET AL. 'Identification of the bile canalicular cell surface molecule GP110 as the ectopeptidase dipeptidyl peptidase IV: an analysis by tissue distribution, purification and N-terminal amino acid sequence.' page 257; column 2; see abstract & HEPATOLOGY (BALTIMORE), vol. 11, no. 4, 1990 pages 534-544, ---	1,5,6,8, 9,13-19
Y	CHEMICAL ABSTRACTS, vol. 114, no. 19, 13 May 1991 Columbus, Ohio, US; abstract no. 181262, S. HARTEL-SCHENK ET AL. 'Development of monoclonal antibodies against different protein and carbohydrate epitopes of dipeptidyl peptidase IV from rat liver plasma membranes.' page 372; column 1; see abstract & EUR. J. BIOCHEM., vol. 196, no. 2, 1991 pages 349-355, ---	1,5,6,8, 9,13-19
Y	US,A,4 361 537 (M. E. DEUTSCH ET AL.) 30 November 1982 cited in the application see the whole document -----	6,9,10, 13-17

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/08898

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US-A-4191808	04-03-80	JP-C-	1077131	25-12-81
		JP-A-	52055593	07-05-77
		JP-B-	56020839	15-05-81
		CA-A-	1080216	24-06-80
		DE-A-	2649171	18-05-77
		FR-A, B	2329646	27-05-77
		GB-A-	1518207	19-07-78
		NL-A-	7612030	03-05-77
		SE-A-	7612064	01-05-77
		US-A-	4119620	10-10-78
US-A-4191809	04-03-80	JP-C-	1356548	13-01-87
		JP-A-	53105477	13-09-78
		JP-B-	61026558	20-06-86
		JP-A-	54005976	17-01-79
		DE-A-	2808111	31-08-78
		FR-A-	2381764	22-09-78
		GB-A-	1547747	27-06-79
		SE-A-	7801997	27-08-78
		US-A-	4147692	03-04-79
US-A-4361537	30-11-82	US-A-	4235601	25-11-80